Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

The conversation is about sourcing and using topical melatonin for retrograde alopecia. Users discuss purchasing options and potential benefits for hair growth.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

The user is seeking advice on improving their hair loss treatment regimen, considering changes to their topical solution, and is curious about others' daily routines and recommendations for medications and supplements. They are contemplating switching Tretinoin for Tazarotene, Latanoprost for Bimatoprost, and possibly adding Alfatradiol, Topical Melatonin, or a topical androgen receptor antagonist.

Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.

The conversation is about the effectiveness of topical melatonin for hair loss. No specific treatments were discussed, only a sarcastic suggestion to go to tropical places and eat coconuts.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

The conversation is about the application timeline for tretinoin and minoxidil. It discusses whether to wait 30 minutes to an hour after applying tretinoin before using minoxidil or to apply tretinoin at night and minoxidil in the morning.

Late 20s woman struggles with worsening hair loss and tried various treatments without success. Now trying spironolactone and ketokonazole shampoo, hoping for improvement.

User on 100mg spiro and oral minox for 2 years, now switching to dut due to low testosterone. Asks if tapering spiro is necessary or can stop immediately.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

A user is considering switching from twice-daily to once-daily application of 5% minoxidil and 0.1% topical finasteride to reduce systemic absorption while maintaining hair regrowth. They seek advice on whether once-daily use is effective for maintaining results.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

The user is on Finasteride for hair loss, taking 0.5mg daily, and plans to reduce the dose to 0.25mg while making lifestyle changes to lower prolactin, SHGB, and cortisol. They will retest in 90 days to assess progress and are open to advice.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

Gut microbiome imbalances can cause scalp inflammation and affect hair follicles, potentially leading to hair loss. Treatments include finasteride, peptides like BPC-157, TB-500, KPV, and lifestyle changes such as diet and exercise.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The conversation discusses recommendations for using topical melatonin for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

User follows a hair loss protocol with topical finasteride, minoxidil, RU58841, stemoxydine, and microneedling. They plan to get a hair transplant at month 9 and ask for opinions on their progress.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

The user is experiencing hair loss and is using oral treatments including 5mg minoxidil, 1.1mg finasteride, and 1mg biotin daily. They are considering adding dutasteride and possibly a hair system, while others suggest patience and additional treatments like microneedling.